# Scholar Rock Holding Corp: financial statements, quarterly

SRRK · Nasdaq · CIK 1727196 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srrk.md) · [Financials](/companies/srrk/financials.md) · [Filings](/companies/srrk/filings.md) · [Insiders](/companies/srrk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/srrk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001104659-25-111935.md) | [0.0 d](/filings/0001104659-26-022551.md) | [0.0](/filings/0001104659-26-056667.md) | [0.0 d](/filings/0001193125-26-336732.md) |
| Research and development | $m | [30.3](/filings/0001558370-24-015155.md) | [35.0 d](/filings/0001558370-25-001682.md) | [43.1](/filings/0001558370-25-007655.md) | [42.4](/filings/0001558370-25-010400.md) | [48.7](/filings/0001104659-25-111935.md) | [50.4 d](/filings/0001104659-26-022551.md) | [48.7](/filings/0001104659-26-056667.md) | [62.4](/filings/0001193125-26-336732.md) | [50.5](/filings/0001104659-25-111935.md) | [46.9 d](/filings/0001104659-26-022551.md) | [51.8](/filings/0001104659-26-056667.md) | [58.2](/filings/0001193125-26-336732.md) |
| Operating income | $m | [(43.7)](/filings/0001558370-24-015155.md) | [(48.0) d](/filings/0001558370-25-001682.md) | [(58.4)](/filings/0001558370-25-007655.md) | [(59.5)](/filings/0001558370-25-010400.md) | [(64.8)](/filings/0001104659-25-111935.md) | [(69.4) d](/filings/0001104659-26-022551.md) | [(77.1)](/filings/0001104659-26-056667.md) | [(112)](/filings/0001193125-26-336732.md) | [(104)](/filings/0001104659-25-111935.md) | [(91.9) d](/filings/0001104659-26-022551.md) | [(102)](/filings/0001104659-26-056667.md) | [(109)](/filings/0001193125-26-336732.md) |
| Interest expense | $m | not reported | not reported | not reported | [1.7](/filings/0001558370-25-010400.md) | [1.7](/filings/0001104659-25-111935.md) | [1.6 d](/filings/0001104659-26-022551.md) | [1.8](/filings/0001104659-26-056667.md) | [1.2](/filings/0001193125-26-336732.md) | [1.3](/filings/0001104659-25-111935.md) | [2.5 d](/filings/0001104659-26-022551.md) | [2.3](/filings/0001104659-26-056667.md) | [4.5](/filings/0001193125-26-336732.md) |
| Net income | $m | [(42.4)](/filings/0001558370-24-015155.md) | [(46.1) d](/filings/0001558370-25-001682.md) | [(56.9)](/filings/0001104659-25-111935.md) | [(58.5)](/filings/0001104659-25-111935.md) | [(64.5)](/filings/0001104659-25-111935.md) | [(66.5) d](/filings/0001104659-26-022551.md) | [(74.7)](/filings/0001193125-26-336732.md) | [(110)](/filings/0001193125-26-336732.md) | [(102)](/filings/0001104659-25-111935.md) | [(91.0) d](/filings/0001104659-26-022551.md) | [(106)](/filings/0001193125-26-336732.md) | [(110)](/filings/0001193125-26-336732.md) |
| Diluted EPS | $ per share | [(0.53)](/filings/0001558370-24-015155.md) | not reported | [(0.59)](/filings/0001558370-25-007655.md) | [(0.60)](/filings/0001558370-25-010400.md) | [(0.66)](/filings/0001104659-25-111935.md) | not reported | [(0.67)](/filings/0001104659-26-056667.md) | [(0.98)](/filings/0001193125-26-336732.md) | [(0.90)](/filings/0001104659-25-111935.md) | not reported | [(0.83)](/filings/0001104659-26-056667.md) | [(0.84)](/filings/0001193125-26-336732.md) |
| Basic EPS | $ per share | [(0.53)](/filings/0001558370-24-015155.md) | not reported | [(0.59)](/filings/0001558370-25-007655.md) | [(0.60)](/filings/0001558370-25-010400.md) | [(0.66)](/filings/0001104659-25-111935.md) | not reported | [(0.67)](/filings/0001104659-26-056667.md) | [(0.98)](/filings/0001193125-26-336732.md) | [(0.90)](/filings/0001104659-25-111935.md) | not reported | [(0.83)](/filings/0001104659-26-056667.md) | [(0.84)](/filings/0001193125-26-336732.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [67.6](/filings/0001558370-24-015155.md) | [102](/filings/0001558370-25-001682.md) | [92.0](/filings/0001558370-25-007655.md) | [93.4](/filings/0001558370-25-010400.md) | [76.4](/filings/0001104659-25-111935.md) | [178](/filings/0001104659-26-022551.md) | [138](/filings/0001104659-26-056667.md) | [153](/filings/0001193125-26-336732.md) | [287](/filings/0001104659-25-111935.md) | [324](/filings/0001193125-26-336732.md) | [431](/filings/0001104659-26-056667.md) | [437](/filings/0001193125-26-336732.md) |
| Current assets | $m | [228](/filings/0001558370-23-017854.md) | [288](/filings/0001558370-25-001682.md) | [247](/filings/0001558370-24-006908.md) | [199](/filings/0001558370-24-011461.md) | [153](/filings/0001558370-24-015155.md) | [451](/filings/0001104659-26-022551.md) | [385](/filings/0001558370-25-007655.md) | [319](/filings/0001558370-25-010400.md) | [391](/filings/0001104659-25-111935.md) | [385](/filings/0001193125-26-336732.md) | [515](/filings/0001104659-26-056667.md) | [507](/filings/0001193125-26-336732.md) |
| Total assets | $m | [251](/filings/0001558370-23-017854.md) | [311](/filings/0001558370-25-001682.md) | [267](/filings/0001558370-24-006908.md) | [227](/filings/0001558370-24-011461.md) | [179](/filings/0001558370-24-015155.md) | [475](/filings/0001104659-26-022551.md) | [408](/filings/0001558370-25-007655.md) | [340](/filings/0001558370-25-010400.md) | [412](/filings/0001104659-25-111935.md) | [404](/filings/0001193125-26-336732.md) | [535](/filings/0001104659-26-056667.md) | [524](/filings/0001193125-26-336732.md) |
| Current liabilities | $m | [26.7](/filings/0001558370-23-017854.md) | [32.7](/filings/0001558370-25-001682.md) | [37.5](/filings/0001558370-24-006908.md) | [33.0](/filings/0001558370-24-011461.md) | [39.4](/filings/0001558370-24-015155.md) | [46.9](/filings/0001104659-26-022551.md) | [37.6](/filings/0001558370-25-007655.md) | [50.4](/filings/0001558370-25-010400.md) | [62.0](/filings/0001104659-25-111935.md) | [55.4](/filings/0001193125-26-336732.md) | [59.6](/filings/0001104659-26-056667.md) | [72.2](/filings/0001193125-26-336732.md) |
| Total liabilities | $m | [83.0](/filings/0001558370-23-017854.md) | [85.8](/filings/0001558370-25-001682.md) | [84.5](/filings/0001558370-24-006908.md) | [93.2](/filings/0001558370-24-011461.md) | [99.9](/filings/0001558370-24-015155.md) | [106](/filings/0001104659-26-022551.md) | [95.2](/filings/0001558370-25-007655.md) | [107](/filings/0001558370-25-010400.md) | [167](/filings/0001104659-25-111935.md) | [159](/filings/0001193125-26-336732.md) | [259](/filings/0001104659-26-056667.md) | [270](/filings/0001193125-26-336732.md) |
| Long-term debt | $m | [50.0](/filings/0001558370-23-017854.md) | [48.7](/filings/0001558370-25-001682.md) | [44.6](/filings/0001558370-24-006908.md) | [48.5](/filings/0001558370-24-011461.md) | [50.1](/filings/0001558370-24-015155.md) | [50.1](/filings/0001104659-26-022551.md) | [49.7](/filings/0001558370-25-007655.md) | [49.8](/filings/0001558370-25-010400.md) | [99.6](/filings/0001104659-25-111935.md) | [99.7](/filings/0001193125-26-336732.md) | [197](/filings/0001104659-26-056667.md) | [196](/filings/0001193125-26-336732.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | [1.3](/filings/0001558370-25-001682.md) | [5.5](/filings/0001558370-24-006908.md) | [1.6](/filings/0001558370-24-011461.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [168](/filings/0001558370-24-015155.md) | [225](/filings/0001104659-26-022551.md) | [183](/filings/0001104659-25-111935.md) | [134](/filings/0001104659-25-111935.md) | [79.2](/filings/0001104659-25-111935.md) | [369](/filings/0001193125-26-336732.md) | [312](/filings/0001193125-26-336732.md) | [233](/filings/0001193125-26-336732.md) | [245](/filings/0001104659-25-111935.md) | [245](/filings/0001193125-26-336732.md) | [276](/filings/0001193125-26-336732.md) | [254](/filings/0001193125-26-336732.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(32.3) d](/filings/0001558370-24-015155.md) | [(37.3) d](/filings/0001558370-25-001682.md) | [(49.8)](/filings/0001558370-25-007655.md) | [(49.2) d](/filings/0001558370-25-010400.md) | [(52.5) d](/filings/0001104659-25-111935.md) | [(49.5) d](/filings/0001104659-26-022551.md) | [(78.7)](/filings/0001104659-26-056667.md) | [(76.9) d](/filings/0001193125-26-336732.md) | [(68.9) d](/filings/0001104659-25-111935.md) | [(75.5) d](/filings/0001104659-26-022551.md) | [(82.1)](/filings/0001104659-26-056667.md) | [(70.3) d](/filings/0001193125-26-336732.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-015155.md) | [0.0 d](/filings/0001558370-25-001682.md) | [0.0](/filings/0001558370-25-007655.md) | [0.0 d](/filings/0001558370-25-010400.md) | [0.0 d](/filings/0001104659-25-111935.md) | [0.0 d](/filings/0001104659-26-022551.md) | [0.3](/filings/0001104659-26-056667.md) | [0.2 d](/filings/0001193125-26-336732.md) | [0.1 d](/filings/0001104659-25-111935.md) | [0.0 d](/filings/0001104659-26-022551.md) | [0.1](/filings/0001104659-26-056667.md) | [0.0 d](/filings/0001193125-26-336732.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [79.3](/filings/0001558370-23-017854.md) | [79.6](/filings/0001558370-24-006908.md) | [80.1](/filings/0001558370-24-011461.md) | [80.6](/filings/0001558370-24-015155.md) | [95.9](/filings/0001558370-25-007655.md) | [96.8](/filings/0001558370-25-010400.md) | [97.1](/filings/0001104659-25-111935.md) | [112](/filings/0001104659-26-056667.md) | [113](/filings/0001193125-26-336732.md) | [114](/filings/0001104659-25-111935.md) | [127](/filings/0001104659-26-056667.md) | [131](/filings/0001193125-26-336732.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 121,785,282 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336732.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.